Navigation Links
Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
Date:7/27/2009

- Management to discuss second quarter financial results -

LAVAL, QC, July 27 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, August 7, 2009 at 8:30 a.m. (ET) to discuss its second quarter 2009 financial results. Labopharm will report its second quarter 2009 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21311012 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
2. Labopharm amends debt facility agreement with Hercules
3. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
4. Labopharm Reports Results for First Quarter Fiscal 2009
5. Labopharm announces details for first quarter results conference call and annual meeting
6. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
7. Labopharm to present at Cowen 29th Annual Health Care Conference
8. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
9. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
10. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
11. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... and characterization laboratories, is now offering HIAC particle counting and sizing services for ... , Gateway Analytical instituted the new service as a response to the needs ...
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... 'Tis ... can disrupt daily routines. That means it's also the season when eating healthy, staying ... living with diabetes) on schedule is harder to do. , "Shopping trips, parties ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD , ... arrival of the newest Sciton laser in January 2017. The Halo is the ... and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo ...
(Date:12/5/2016)... ... , ... Researchers at Johns Hopkins All Children’s Hospital want to learn more ... course of three years, researchers will study concussions and changes in brain function by ... special sensors, will track the location and force of the hit. The sensors store ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... founder of Spectrum Science Communications , announced today that ... two consecutive years of high double digit growth in fee revenues. ... assumed management of the firm that Seng founded in 1996. Earlier ... of the Year and was selected among the Best Places to ... ...
Breaking Medicine Technology: